SHINE is drawing renewed attention for its fusion-based isotope production as the US works to localize Mo-99 and reduce dependence on foreign reactors—an important shift for the nuclear medicine supply chain that underpins most diagnostic procedures...

Published by Nucleation Capital in Advanced Nuclear, Advanced Nuclear Customers, Fusion, Medical Isotopes, NEWS, Nuclear competitiveness, Nuclear innovation, Nuclear R&D, Portfolio Venture, Private companies, US competitiveness, US technological leadership